By IDSE News Staff
SAN DIEGO—Switching to the investigational single-tablet regimen containing darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF) was as effective as continuing treatment with a boosted protease inhibitor (PI) plus emtricitabine and tenofovir disoproxil fumarate in HIV-positive, virologically suppressed adults, according to a study presented at IDWeek 2017 (abstract 07AB).
The phase 3 EMERALD trial met its primary end point, which focused on virologic